Scarica l'app Stockscreener
9.30
0.98%
0.09
Dopo l'orario di chiusura:
9.30
Actuate Therapeutics Inc Borsa (ACTU) Ultime notizie
Actuate Therapeutics to Host KOL Event on Topline Phase 2 - GlobeNewswire
Actuate Therapeutics to host KOL event on Phase 2 elraglusib data - TipRanks
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data - Endpoints News
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Actuate stock jumps after cancer trial data (ACTU:NASDAQ) - Seeking Alpha
Elraglusib shows survival benefit in pancreatic cancer trial - Investing.com Australia
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
Actuate Therapeutics to Present Topline Phase 2 Data of Elraglusib at 2025 ASCO Annual Meeting - Nasdaq
Actuate to Present Elraglusib Phase 2 Topline Data at the - GlobeNewswire
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at Craig Hallum - Defense World
Craig-Hallum sets $21 target on Actuate Therapeutics stock By Investing.com - Investing.com Canada
What Will Actuate Therapeutics Inc (NASDAQ: ACTU) Be Like In 2025 - stocksregister.com
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Actuate Therapeutics to Present Elraglusib Data for Advanced Salivary Gland Carcinoma at AACR Annual Meeting 2025 - Nasdaq
Actuate to Present Promising Data on Elraglusib in Advanced - GlobeNewswire
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 - Yahoo Finance
Actuate Therapeutics (NASDAQ:ACTU) Trading 6% Higher – Still a Buy? - Defense World
Bone Metastasis in Solid Tumors Market Set to Grow Substantially - openPR.com
Bone Metastasis in Solid Tumors Market Set to Grow Substantially Through 2034, DelveInsight Projects | NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS - Barchart.com
Will Actuate's Elraglusib Prove To Be A Game Changer In The Fight Against Aggressive Cancers? - RTTNews
Soft Tissue Sarcoma with Lung Metastases Treatment Market Size - openPR.com
Bone Metastasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Statistics, Revenue, Therapies, Treatment, Companies by DelveInsight - Barchart.com
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - Marketscreener.com
Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC - MarketScreener
Growth Driver In The Locally Advanced Pancreatic Cancer Market 2 - News Channel Nebraska Southeast
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (NASDAQ:ACTU) - Seeking Alpha
Brokers Set Expectations for ACTU Q1 Earnings - Defense World
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR.com
WIN Consortium leading the future of precision cancer medicine - EurekAlert
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy Recommendation - Nasdaq
Actuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic Cancer - TipRanks
Actuate Therapeutics Inc. (ACTU) reports earnings - Quartz
ACTUATE THERAPEUTICS, INC. SEC 10-K Report - TradingView
Pre-market Movers: AWH, TSVT, CUTR, SNOA... - RTTNews
Neuroblastoma Pipeline 2025: Key Companies, MOA, ROA, - openPR
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Dollar Retreats on Growth Risk From US Tariffs - The Globe and Mail
Zoom Stock: Leading the Video Market After Skype’s Exit - The Globe and Mail
Pancreatic And Bile Duct Cancer Drug Market Enhancing Cybersecurity and Cloud Integration for the Future - ExpressVartha
Actuate reports progress in pancreatic cancer trial By Investing.com - Investing.com Australia
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Actuate Announces Completion of Enrollment in a Phase 2 - GlobeNewswire
Actuate reports progress in pancreatic cancer trial - Investing.com India
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer - Yahoo Finance
0.88%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):